By Adria Calatayud

Roche Holding said it received approval from the U.S. Food and Drug Administration for Vabysmo as treatment of macular edema following retinal vein occlusion, the drug's third indication.

The Swiss pharmaceutical giant said Friday that the approval was based on two late-stage studies that demonstrated early and sustained vision improvements.

Vabysmo is already approved for so-called "wet" age-related macular degeneration and diabetic macular edema, Roche said.

Write to Adria Calatayud at adria.calatayud@dowjones.com

(END) Dow Jones Newswires

October 27, 2023 01:25 ET (05:25 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
過去 株価チャート
から 5 2024 まで 5 2024 Roche (QX)のチャートをもっと見るにはこちらをクリック
Roche (QX) (USOTC:RHHBY)
過去 株価チャート
から 5 2023 まで 5 2024 Roche (QX)のチャートをもっと見るにはこちらをクリック